Cipla gets USFDA nod for generic Difluprednate Ophthalmic Emulsion

The product will be available for shipping soon, the Mumbai-based drug major said

Picture: Pixabay

Last Updated on November 28, 2021 by The Health Master

Drug firm Cipla on Thursday said it has received approval from the US health regulator to market Difluprednate Ophthalmic Emulsion, used in the treatment of inflammation and pain associated with ocular surgery, in the American market.

The company has received final approval from the US Food and Drug Administration (USFDA) to market its product which is a generic version of Novartis Pharmaceutical Corporation’s Durezol, Cipla said in a statement.

The product is also used for the treatment of endogenous anterior uveitis.

According to IQVIA (IMS Health), Durezol had US sales of around USD 106 million for the 12-month period ending June 2021.

The product will be available for shipping soon, the Mumbai-based drug major said.

Shares of Cipla were trading 0.29 per cent up at Rs 912.90 apiece on the BSE.

Alembic gets USFDA nod for Clomipramine HCL Capsules

Zydus Cadila gets final nod from USFDA for Fulvestrant injection

USFDA inspection ends with ‘Zero’ observations: Alkem

Granules Pharma clears USFDA audit

Zydus Cadila gets USFDA nod for Ibrutinib tablets

Lupin gets USFDA nod for generic Antifungal drug

Latest Notifications regarding Pharmaceuticals

Why to include Peptides in your Skincare Products ?

DCGI classifies 135 Ophthalmology, 51 respiratory Medical Devices

Govt approves Bharat Biotech’s plant for Covaxin production

PLI scheme for 100 Chemicals, APIs and Intermediates to be formulated…

Lok Sabha passes amendment bills on Homoeopathy, National Commission for Indian…

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon
YouTube Icon

Enter your email address:

Delivered by FeedBurner